Pharmaceutical API raw material Powder palmitamide mea

CAS:544-31-0

MF:C18H37NO2

MW:299.49

EINECS:208-867-9

Specification: 99% min palmitamide mea Powder

Sample:palmitamide mea Powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance:white powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

palmitamide mea powder Usage and Synthesis.

Cetamide ethanol is an organic synthesis intermediate and pharmaceutical intermediate, which can be used in laboratory research and development process and chemical pharmaceutical research and development process. PEA has been shown to have anti-inflammatory, anti-sensory injury, neuroprotective, and anticonvulsant properties. PEA has been exploring various pain states in people in different clinical trials on inflammation and pain syndromes.

Uses of palmitamide mea.

‌Anti-inflammatory effect‌: Palmitamide MEA can inhibit the release of pro-inflammatory mediators, thereby reducing skin inflammation, which is very beneficial for reducing skin redness, pain and discomfort.
‌Antibacterial and antimicrobial activity‌: It has the ability to fight harmful microorganisms on the skin, which helps maintain skin health and reduce skin problems caused by microbial infections.
‌Skin repair and regeneration‌: Palmitamide MEA can resuscitate peroxisome proliferator resuscitation receptor-α (PPAR-α), further exert its biological effects, help repair and regenerate the skin, and make the skin healthier and smoother.
‌Skin soothing‌: By binding to the mast cell CB2 receptor, Palmitamide MEA can relieve itching, inhibit histamine release and vasodilation, thereby achieving the effect of soothing skin redness.
‌Enhance skin barrier function‌: It can stimulate the production of signaling molecules PPAR, restore the disordered skin lipids of damaged skin to normal, thereby enhancing the skin barrier function and preventing recurrence.

In vitro study of palmitamide mea.

PEA can effectively prevent glutamate toxicity of rat cerebellar granule cells and enhance the motility of microglia. In mitochondrial fragments of cells stimulated with PEA, expressions of steroid synthesis Rapid regulatory protein (StAR) and P450scc were increased, including some of the proteins responsible for the formation of neurosteroids. PEA also has a protective effect, such as reducing malondialdehyde formation in cells treated with L-buthionine-(S,R)-sulfoximine, which causes glutathione deficiency. The effect of PEA is partially inhibited by finasteride (5A-reductase inhibitor).